Amneal Pharmaceuticals Inc. (NYSE:AMRX) and Agile Therapeutics Inc. (NASDAQ:AGRX) have been rivals in the Drugs – Generic for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals Inc.	1.66B	2.41	20.92M	-4.28	0.00
Agile Therapeutics Inc.	N/A	0.00	19.78M	-0.65	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has Amneal Pharmaceuticals Inc. and Agile Therapeutics Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals Inc.	-1.26%	-184%	-12.5%
Agile Therapeutics Inc.	0.00%	-76.3%	-54.9%

Volatility & Risk

Amneal Pharmaceuticals Inc. has a beta of 1.34 and its 34.00% more volatile than Standard and Poor’s 500. Agile Therapeutics Inc. on the other hand, has 0.4 beta which makes it 60.00% less volatile compared to Standard and Poor’s 500.

Liquidity

Amneal Pharmaceuticals Inc.’s Current Ratio is 1.9 while its Quick Ratio is 1.3. On the competitive side is, Agile Therapeutics Inc. which has a 2.1 Current Ratio and a 2.1 Quick Ratio. Agile Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Amneal Pharmaceuticals Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Amneal Pharmaceuticals Inc. and Agile Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Amneal Pharmaceuticals Inc.	0	0	1	3.00
Agile Therapeutics Inc.	0	0	2	3.00

$16 is Amneal Pharmaceuticals Inc.’s average target price while its potential upside is 19.23%. Competitively the average target price of Agile Therapeutics Inc. is $3.5, which is potential 136.49% upside. The information presented earlier suggests that Agile Therapeutics Inc. looks more robust than Amneal Pharmaceuticals Inc. as far as analyst opinion.

Institutional and Insider Ownership

Amneal Pharmaceuticals Inc. and Agile Therapeutics Inc. has shares held by institutional investors as follows: 0% and 44.2%. 0.1% are Amneal Pharmaceuticals Inc.’s share held by insiders. Competitively, Agile Therapeutics Inc. has 1.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Amneal Pharmaceuticals Inc.	-2.05%	5.29%	-31.88%	-43.04%	-34.2%	-4.43%
Agile Therapeutics Inc.	18.86%	37.04%	37.04%	311.11%	-69.25%	92.74%

For the past year Amneal Pharmaceuticals Inc. had bearish trend while Agile Therapeutics Inc. had bullish trend.

Summary

Agile Therapeutics Inc. beats on 7 of the 10 factors Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.